Letter to the Editor
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Mar 7, 2025; 31(9): 100607
Published online Mar 7, 2025. doi: 10.3748/wjg.v31.i9.100607
Strengths, weaknesses, opportunities, and threats analysis of combination therapy for inflammatory bowel disease
Jia-Wang Yan, Mei Nie, Hang Zhang, Yan-Miao Liu, Fu-Shan Tang
Jia-Wang Yan, Mei Nie, Hang Zhang, Fu-Shan Tang, Department of Clinical Pharmacy, Zunyi Medical University, Zunyi 563006, Guizhou Province, China
Jia-Wang Yan, Mei Nie, Hang Zhang, Yan-Miao Liu, Fu-Shan Tang, Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi 563006, Guizhou Province, China
Jia-Wang Yan, Mei Nie, Hang Zhang, Yan-Miao Liu, Fu-Shan Tang, Key Laboratory of Basic Pharmacology of Guizhou Province and School of Pharmacy, Zunyi Medical University, Zunyi 563006, Guizhou Province, China
Yan-Miao Liu, The First Clinical Institute, Zunyi Medical University, Zunyi 563006, Guizhou Province, China
Author contributions: Yan JW contributed to the initial drafting and revision of the manuscript; Nie M, Zhang H, and Liu YM participated in discussions and contributed to manuscript revisions; Tang FS contributed to idea generation, manuscript revision, and provided supervision; all authors have reviewed and approved the final version of the manuscript.
Conflict-of-interest statement: The authors declare that they have no conflict of interest to disclose.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Fu-Shan Tang, PhD, Professor, Department of Clinical Pharmacy, Zunyi Medical University, No. 6 Xuefu West Road, Xinpu New District, Zunyi 563006, Guizhou Province, China. fstang@vip.163.com
Received: August 21, 2024
Revised: January 12, 2025
Accepted: January 18, 2025
Published online: March 7, 2025
Processing time: 181 Days and 5.2 Hours
Core Tip

Core Tip: Ongoing advancements in medical research have solidified drug combination therapy as pivotal in the management of inflammatory bowel disease (IBD). This editorial evaluates the current landscape of IBD combination therapy using the strengths, weaknesses, opportunities, and threats analysis and proposes pathways to enhance the next generation of treatment strategies.